{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:58:52Z","timestamp":1794808732774,"version":"4.9.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,21]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The phase 3 randomized, active-controlled GS-US-380-1844 (NCT02603120) study evaluated switching to the single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) among people with HIV-1. Previously, results from the 48-week double-blind phase showed that switching to B\/F\/TAF was noninferior to remaining on DTG\/ABC\/3TC and that B\/F\/TAF was well tolerated. Here, we show the long-term safety and efficacy of switching to B\/F\/TAF from DTG\/ABC\/3TC among people with HIV-1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Participants were virologically suppressed people with HIV-1 (HIV-1 RNA &lt;50 copies\/mL for \u2265 3 months prior to screening) receiving DTG\/ABC\/3TC at baseline. Participants were randomized 1:1 to switch to B\/F\/TAF or remain on DTG\/ABC\/3TC. Following 48 weeks of treatment with B\/F\/TAF or DTG\/ABC\/3TC in the double-blind phase, participants had the option to enter an open-label extension phase, during which they received B\/F\/TAF. Virologic, immunologic, and safety outcomes during treatment with B\/F\/TAF through the open-label extension up to 168 weeks, including preexisting and treatment-emergent resistance, were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 547 participants in the all-B\/F\/TAF analysis set, virologic suppression (HIV-1 RNA\u2005&lt;\u200550\u2005copies\/mL) was maintained in 99% to 100% of participants up to 168 weeks into B\/F\/TAF treatment, including in those with preexisting resistance; no treatment-emergent resistance was detected. CD4 cell counts remained stable during B\/F\/TAF treatment, with median (interquartile range) changes from baseline of \u221217 (\u2212120, 65) cells\/\u00b5L at week 48 and \u22129 (\u2212100, 108) cells\/\u00b5L at week 96. Safety and tolerability findings were consistent with previously reported findings up to week 48; most drug-related adverse events were grade 1 or 2 in severity; no new safety signals were identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Switching to B\/F\/TAF from DTG\/ABC\/3TC was associated with continued high rates of virologic suppression up to week 168, with no treatment-emergent resistance. B\/F\/TAF was well tolerated throughout the study period.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041482","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:02:27Z","timestamp":1740409347000},"page":"e41482","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir\/abacavir\/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-6457","authenticated-orcid":false,"given":"Indira","family":"Brar","sequence":"first","affiliation":[{"name":"Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ruane","sequence":"additional","affiliation":[{"name":"Ruane Clinical Research Group, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mezgebe","family":"Berhe","sequence":"additional","affiliation":[{"name":"North Texas Infectious Diseases Consultants, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[{"name":"Central Texas Clinical Research, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Benson","sequence":"additional","affiliation":[{"name":"Be Well Medical Center, Berkley, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Henry","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Andreatta","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Research Center, Fort Pierce, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.","volume":"77","author":"Thoueille","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1744-8603-7-31","article-title":"HIV\/AIDS, chronic diseases and globalisation.","volume":"7","author":"Colvin","year":"2011","journal-title":"Global Health"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"R4-20250805","article-title":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV."},{"key":"R5-20250805","article-title":"EACS guidelines (version 12.0),"},{"key":"R6-20250805","article-title":"Biktarvy: prescribing information."},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40121-021-00419-5","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV aged \u226565 years: week 48 results of a phase 3b, open-label trial.","volume":"10","author":"Maggiolo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus.","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial.","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-20250805","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age.","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.","volume":"88","author":"Hagins","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"R15-20250805","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients.","volume":"36","author":"Mic\u00e1n","year":"2022","journal-title":"AIDS"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV.","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R19-20250805","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile.","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250805","first-page":"e02406","article-title":"Long dissociation of bictegravir from HIV-1 integrase-DNA complexes.","volume":"65","author":"White","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20250805","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/QAD.0b013e32833adbcf","article-title":"Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.","volume":"24","author":"Lok","year":"2010","journal-title":"AIDS"},{"key":"R22-20250805","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12979-021-00260-x","article-title":"The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study.","volume":"19","author":"Chen","year":"2022","journal-title":"Immun Ageing"},{"key":"R23-20250805","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"R24-20250805","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"R25-20250805","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence.","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R26-20250805","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:23:52Z","timestamp":1754414632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041482","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}